Black Diamond Therapeutics (BDTX) EPS (Basic) (2018 - 2021)
Historic EPS (Basic) for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q4 2021 value amounting to -$0.71.
- Black Diamond Therapeutics' EPS (Basic) fell 654.4% to -$0.71 in Q4 2021 from the same period last year, while for Dec 2021 it was -$3.26, marking a year-over-year decrease of 6186.91%. This contributed to the annual value of -$3.47 for FY2021, which is 6926.83% down from last year.
- According to the latest figures from Q4 2021, Black Diamond Therapeutics' EPS (Basic) is -$0.71, which was down 654.4% from -$0.95 recorded in Q3 2021.
- In the past 5 years, Black Diamond Therapeutics' EPS (Basic) registered a high of -$0.41 during Q2 2020, and its lowest value of -$5.99 during Q2 2019.
- Its 4-year average for EPS (Basic) is -$1.93, with a median of -$0.94 in 2021.
- As far as peak fluctuations go, Black Diamond Therapeutics' EPS (Basic) plummeted by 20662.25% in 2019, and later soared by 9315.53% in 2020.
- Quarter analysis of 4 years shows Black Diamond Therapeutics' EPS (Basic) stood at -$1.51 in 2018, then tumbled by 206.62% to -$4.63 in 2019, then surged by 85.61% to -$0.67 in 2020, then decreased by 6.54% to -$0.71 in 2021.
- Its EPS (Basic) stands at -$0.71 for Q4 2021, versus -$0.95 for Q3 2021 and -$0.93 for Q2 2021.